Patents Prove SARS-CoV-2 Is a Manufactured Virus


by Dr. Joseph Mercola, Mercola:

  • Hundreds of patents show SARS-CoV-2 is a manmade virus that has been tinkered with for decades. Much of the research was funded by the National Institutes of Allergy and Infectious Diseases (NIAID) under the direction of Dr. Anthony Fauci, and may have been an outgrowth of attempts to develop an HIV vaccine
  • In 1999, Fauci funded research at University of North Carolina Chapel Hill to create “an infectious replication-defective coronavirus” specifically targeted for human lung epithelium. This appears to be the virus that became known as SARS-CoV
  • U.S. Patent 7279327 shows we knew the ACE receptor, the ACE2 binding domain, the S-1 spike protein, and other elements of SARS-CoV-2 were engineered and could be synthetically modified using gene sequencing technologies
  • The CDC holds patents to a SARS coronavirus that is 89% to 99% identical to the sequence identified as SARS-CoV-2, as well as the PCR test to diagnose it
  • 120 patents detail supposed “unique” features of SARS-CoV-2: the polybasic cleavage site, the spike protein and the ACE2 binding, proving it’s not a novel virus at all


In a January 2021 lecture, Jonathan Latham, Ph.D., introduced the term “the pandemic virus industrial complex,” to describe the academic, military and commercial complexes that are driving the pandemic agenda and obscuring facts that indicate SARS-CoV-2 is a manmade virus.

In the video above, David E. Martin, Ph.D., introduces shocking evidence that SARS-CoV-2 is indeed a manmade bioweapon, and has been in the works for decades. Much of this research was funded by none other than the National Institutes of Allergy and Infectious Diseases (NIAID) under the direction of Dr. Anthony Fauci.

Pandemic virus industrial complex indeed! You do not want to miss this bombshell interview, conducted by Reiner Fuellmich,1 founding member of the German Corona Extra-Parliamentary Inquiry Committee2,3 (Außerparlamentarischer Corona Untersuchungsausschuss or ACU4). A transcript5 is available if you prefer to read it.

SARS-CoV-2 Is Not a Novel Coronavirus at All

Martin has been in the business of tracking patent applications and approvals since 1998. His company, M-Cam International Innovation Risk Management, is the world’s largest underwriter of intangible assets used in finance in 168 countries. M-Cam has also monitored biological and chemical weapons treaty violations on behalf of the U.S. government, following the anthrax scare in September 2001.

According to Martin, there are more than 4,000 patents relating to the SARS coronavirus. His company has also done a comprehensive review of the financing of research involving the manipulation of coronaviruses that gave rise to SARS as a subclade of the beta coronavirus family.

In his testimony to ACU, he reviews some of the most pertinent patents, showing SARS-CoV-2 is not a novel coronavirus at all but, rather, a manmade virus that has been in the works for decades.

A comprehensive list of 120 patents relating to SARS-CoV-2-associated features can be found here.6 The features patented are referenced in two key scientific papers, “A Novel Bat Coronavirus Reveals Natural Insertions at the S1/S2 2 Cleavage Site of the Spike Protein and a Possible Recombinant 3 Origin of HCoV-19,” and “The Proximal Origin of SARS-CoV-2.”

On that list, we see numerous patents detailing manipulation of the polybasic cleavage site for SARS-CoV, the spike protein, as well as ACE2 binding, all three of which are supposed to be unique features of SARS-CoV-2. As explained by Martin:

“We took the reported gene sequence, which was reportedly isolated as a novel virus, indicated as such by the ICTV, the International Committee on Taxonomy of Viruses of the World Health Organization. We took the actual genetic sequences that were reportedly novel and reviewed those against the patent records that were available as of the spring of 2020.

And what we found, as you’ll see in this report, are over 120 patented pieces of evidence, to suggest that the declaration of a ‘novel coronavirus’ was actually entirely a fallacy.

There was no novel coronavirus. There are countless, very subtle modifications of coronavirus sequences that have been uploaded, but there was no single identified ‘novel coronavirus’ at all.

As a matter of fact, we found records in the patent records, of sequences attributed to novelty, going to patents that were sought as early as 1999. So not only was this not a novel anything … it’s not been novel for over two decades.”

Spike Protein Vaccine for Coronavirus Patented 22 Years Ago

Up until 1999, coronavirus patents were all in the veterinary sciences. The first coronavirus vaccine to use the S spike protein was patented by Pfizer in January 2000 (Patent No. 6372224). It was a spike protein virus vaccine for canine coronavirus. You can look up the actual patents for yourself on the United States Patent and Trademark Office’s website,7 if you like.

“Ralph Baric’s work on … rabbit cardiomyopathy … and then canine coronavirus in Pfizer’s work, to identify how to develop S spike protein vaccine target candidates, [give] rise to the obvious evidence that …

… neither the coronavirus concept of a vaccine, nor the principle of the coronavirus itself, as a pathogen of interest with respect to the spike proteins behavior, is anything novel at all. As a matter of fact, it’s 22 years old based on patent filings,” Martin says.

From HIV Vaccine Development to COVID-19

According to Martin, Fauci and the NIAID “found the malleability of coronavirus to be a potential candidate for HIV vaccines,” and in 1999, Fauci funded research at University of North Carolina Chapel Hill (where Baric has a lab) to create “an infectious replication-defective coronavirus” specifically targeted for human lung epithelium.

The patent for that replication-defective coronavirus that attacks human lung cells was filed April 19, 2002 (Patent No. 7279327). “In other words, we made SARS,” Martin says. Or perhaps more accurately, Fauci and UNC did. Several months after that patent filing, the SARS outbreak in Asia occurred.

“That patent, issued as U.S. Patent 7279327 … clearly lays out in very specific gene sequencing, the fact that we knew that the ACE receptor, the ACE2 binding domain, the S-1 spike protein, and other elements of what we have come to know as this scourge pathogen, was not only engineered, but could be synthetically modified in the laboratory using nothing more than gene sequencing technologies.

Taking computer code and turning it into a pathogen, or an intermediate of the pathogen, and that technology was funded exclusively, in the early days, as a means by which we could harness coronavirus as a vector to distribute HIV vaccine.”

Coronavirus — A Biological Weapon Candidate Since 2001?

As mentioned, Martin has monitored biological and chemical treaty violations since 2001, following the anthrax attacks. Throughout the fall of 2001, an “enormous number” of bacterial and viral pathogens were patented through the National Institutes of Health, the NIAID, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and their international collaborators.

“Our concern was that coronavirus was being seen as not only a potential manipulatable agent for potential use as a vaccine vector, but it was also very clearly being considered as a biological weapon candidate,” Martin says.

Before the SARS outbreak in China, Martin reported these concerns publicly. “So, you can imagine how disappointed I am to be sitting here … having 20 years earlier pointed that there was a problem looming on the horizon with respect to coronavirus,” he says.

Read More @